KPI Measures Sample Clauses

KPI Measures. During each Measurement Period, Amdocs shall summarize the average response time for the Retail trail files delivered to Sprint. Table 8.1: Individual KPI BGYR State [**] Blue [**] Green [**] Yellow [**] Red [**] Table 8.2: Amdocs 76 SLA Management Sprint Schedule C Creditable Performance Specifications (CPS) Individual KPI BGYR State [**] Blue [**] Green [**] Yellow [**] Red [**]
AutoNDA by SimpleDocs
KPI Measures. Set forth below is a chart [**]. KPI BGYR State [**] Blue [**] Green [**] Yellow [**] Red [**] Amdocs 92 SLA Management Sprint Schedule C Creditable Performance Specifications (CPS)
KPI Measures. The Individual KPI BGYR State shall be the least favorable BGYR State with respect to Amdocs’ VAD (Fulfillment) Timeliness performance for all subscriber orders. Set forth below is a chart depicting the KPI measures and the related BGYR States. [**] Individual KPI BGYR State [**] Blue [**] Green [**] Yellow [**] Red [**] Amdocs 93 SLA Management Sprint Schedule C Creditable Performance Specifications (CPS)
KPI Measures. During each Measurement Period, Amdocs shall deliver [**] per table below. Individual KPI BGYR State [**] [**] Blue [**] [**] Green [**] [**] Yellow [**] [**] Red [**] [**] Amdocs 78 SLA Management Schedule C2-WHL Wholesale Creditable Performance Specifications (CPS) [Effective as of January 1, 2014] Version 1.0 Document Number: document_center\0 Creation Date: September 27, 2012 Author: Amdocs Service Level Management Team & Sprint Vendor Management Team Last Edit Date: October 1, 2012 File Name: Sprint_Amdocs_Schedule_C2 Wholesale_FINAL Implementation Date: Sprint Sign-off Date: Amdocs Sign-off Date: Table of Contents Amdocs Sprint Schedule C2-WHL – Wholesale Creditable Performance Specifications (CPS) 1
KPI Measures. Each Measurement Period, Amdocs shall summarize the average response time for the Wholesale trail files delivered to Sprint. Individual KPI BGYR State [**] Blue [**] Green [**] Yellow [**] Red [**] Amdocs 42 SLA Management Schedule C2-Pre Prepaid Creditable Performance Specifications (CPS) [EFFECTIVE AS OF JANUARY 1, 2014] Document Number: document_center\0 Creation Date: September XX, 2012 Author: Amdocs Service Level Management Team & Sprint Vendor Management Team Last Edit Date: October 1, 2012 File Name: Sprint_Amdocs_Schedule C2_Prepaid_FINAL Implementation Date: Sprint Sign-off Date: Amdocs Sign-off Date:
KPI Measures. During each Measurement Period, Amdocs shall deliver [**] per table below. Individual KPI BGYR State [**] [**] Blue [**] [**] Green [**] [**] Yellow [**] [**] Red [**] [**] Amdocs 47 SLA Management SCHEDULE D1 CHARGES [EXPIRING AS OF JANUARY 31, 2014] CAPITALIZED TERMS USED HEREIN NOT OTHERWISE DEFINED WILL HAVE THE MEANING SET FORTH IN THE AGREEMENT.

Related to KPI Measures

  • Measures Prior to resumption of normal performance, the Parties shall continue to perform their obligations under this Agreement to the extent not excused by such event of Force Majeure.

  • Mitigation Measures Company shall take commercially reasonable measures (except measures causing it to incur out-of-pocket expenses which BNYM does not agree in advance to reimburse) to mitigate losses or potential losses to BNYM, including taking verification, validation and reconciliation measures that are commercially reasonable or standard practice in the Company’s business.

  • Performance Measures The extent, if any, to which you shall have the right to payment of the Award shall depend upon your satisfying one of the continuous employment conditions set forth in Section 3 and the extent to which the applicable performance measure has been satisfied as of the Final Measurement Date, as specified below: The Award shall have the following performance measures during the Measurement Period:

  • Security Measures Lessee hereby acknowledges that the rental payable to Lessor hereunder does not include the cost of guard service or other security measures, and that Lessor shall have no obligation whatsoever to provide same. Lessee assumes all responsibility for the protection of the Premises, Lessee, its agents and invitees and their property from the acts of third parties.

  • Performance Measure The number of Performance Shares earned at the end of the three-year Performance Period will vary depending on the degree to which cumulative adjusted earnings per share performance goals for the Performance Period, as established by the Committee, are met.

  • Targets On or before the date that is nine (9) months after the Amendment Date to Amendment No. 2 to this Agreement, LOXO shall designate six (6) Targets from Exhibit B for which research activities will be discontinued. Upon such designation, such discontinued Targets shall cease to be Targets under this Agreement, and Exhibit B shall be deemed to be updated accordingly. On or before the date that is eighteen (18) months after the Amendment Date to Amendment No. 2 to this Agreement, LOXO shall designate two (2) additional Targets from Exhibit B for which research activities will be discontinued; provided, however, that if on or before the date that is eighteen (18) months after the Amendment Date to Amendment No. 2 to this Agreement Loxo provides to Array written notice and a payment of [***] (the “Extension Payment”), Loxo will only be required to designate one (1) additional Target from Exhibit B for which research activities will be discontinued at the end of such eighteen (18) months. Upon such designation, such additional discontinued Target(s) shall cease to be Target(s) under this Agreement, and Exhibit B shall be deemed to be updated accordingly. If Loxo made the Extension Payment, then on or before the date that is [***] after the Amendment Date to Amendment No. 2 to this Agreement, Loxo shall designate one (1) additional Target from Exhibit B for which research activities will be discontinued unless Loxo provides to Array written notice and a payment of [***] (“Additive Payment”) in which case Loxo will not need to designate any more Targets from Exhibit B for discontinuation of research activities. Until such time as the eight (8) Targets (or seven (7) Targets if Loxo has made the Extension Payment and Additive Payment) have been designated for discontinuation, and notwithstanding Section 8.2.1 to the contrary, Loxo shall only have the right, at its discretion, to file provisional patent applications covering the applicable Active Compounds to the Targets from Exhibit B and will not convert such provisional patent applications to a non-provisional patent application or otherwise prosecute any non-provisional patent application covering such Active Compounds. During the Discovery Program Term, Loxo may determine in its sole discretion that research activities with respect to one (1) particular Target on Exhibit B should be discontinued [***] Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. (for example, and without limitation, such Target has not yielded sufficient progress, or scientific literature suggests the Target is intractable or is not therapeutically relevant or for safety issues) and replaced with a different target. Upon any such determination, Loxo shall provide written notice to Array of the one (1) Target that Loxo desires to remove from Exhibit B and will include in such notification a suggested substitute for such discontinued Target. After receipt of such notice, Array will promptly inform Loxo whether, as of the date of such written notice, the addition of such suggested substitute target would not (i) violate any agreement that Array has with a Third Party; (ii) add a target that is the subject of Array’s own active and ongoing research (with existing commitment and expenditure of resources for such target), was the subject of previous significant research at Array, or is the subject of drugs in Array’s clinical development pipeline or marketed product portfolio; or (iii) add a target with respect to which Array is engaged in active, ongoing substantial negotiations (i.e., has agreed a term sheet containing material business terms) with a Third Party. If neither (i), (ii) or (iii) apply to such suggested substitute target, then the discontinued Target shall cease to be a Target, the suggested substitute target shall be deemed a Target for the purposes of this Agreement, and Exhibit B shall be deemed to be updated accordingly. If a proposed target is not available for inclusion, then the fact that Loxo proposed such target or is otherwise interested in such target (or molecules directed to such target) shall be Loxo’s Confidential Information.

  • Access Controls a. Authorized Access - DST shall have controls that are designed to maintain the logical separation such that access to systems hosting Fund Data and/or being used to provide services to Fund will uniquely identify each individual requiring access, grant access only to authorized personnel based on the principle of least privileges, and prevent unauthorized access to Fund Data.

  • Performance Targets Threshold, target and maximum performance levels for each performance measure of the performance period are contained in Appendix B.

  • Safeguards To the extent the Asset Representations Reviewer receives Personally Identifiable Information in the performance of services under this Agreement, the Asset Representations Reviewer represents and warrants that it has, and will continue to have adequate administrative, technical, and physical safeguards: (i) to ensure the security and confidentiality of Personally Identifiable Information; (ii) to protect against any anticipated threats or hazards to the security or integrity of Personally Identifiable Information; and (iii) to protect against unauthorized acquisition of, access to or use of Personally Identifiable Information which could result in a “breach” as that term is defined under applicable Privacy Laws.

  • KEY PERFORMANCE INDICATORS (a) The Custodian and the Funds may from time to time agree to document the manner in which they expect to deliver and receive the services contemplated by this Agreement. The parties agree that any such key performance indicators (hereinafter referred to as “KPIs” or, individually as a “KPI”) shall be agreed upon in writing by the parties and shall be reflected in one or more schedules to this Agreement. The Custodian and the Funds acknowledge that any failure to perform in accordance with KPIs shall not in and of itself be considered a breach of contract that gives rise to contractual or other remedies provided that such failure may be a breach giving rise to contractual or other remedies if it is persistent and not remedied after consultation. Nothing in this Section 11 shall modify any party’s applicable standard of care under this Agreement; nor shall any meeting or discussion among the parties regarding KPIs be construed to prevent a party from pursuing any remedy otherwise available to it pursuant to this Agreement.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!